AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was the target of a significant drop in short interest in September. As of September 29th, there was short interest totalling 8,289,832 shares, a drop of 23.6% from the September 15th total of 10,847,618 shares. Based on an average daily trading volume, of 2,356,573 shares, the days-to-cover ratio is currently 3.5 days. Currently, 8.6% of the shares of the stock are sold short.

A number of brokerages have recently weighed in on AVEO. Piper Jaffray Companies set a $2.00 price target on AVEO Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Seaport Global Securities restated a “buy” rating on shares of AVEO Pharmaceuticals in a research report on Friday, October 6th. FBR & Co restated a “buy” rating and issued a $3.00 price target on shares of AVEO Pharmaceuticals in a research report on Friday, June 30th. ValuEngine upgraded AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 24th. Finally, BidaskClub upgraded AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $3.42.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Fore Research & Management LP purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at $111,000. Clear Harbor Asset Management LLC purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at $289,000. Cannell Peter B & Co. Inc. lifted its holdings in shares of AVEO Pharmaceuticals by 22.9% during the second quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 20,500 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at $184,000. Finally, UBS Oconnor LLC purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at $291,000. 53.76% of the stock is owned by institutional investors and hedge funds.

AVEO Pharmaceuticals (NASDAQ AVEO) opened at 3.68 on Friday. The stock’s market cap is $435.37 million. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $4.24. The stock has a 50 day moving average price of $3.65 and a 200-day moving average price of $2.01.

COPYRIGHT VIOLATION WARNING: “AVEO Pharmaceuticals, Inc. (AVEO) Short Interest Update” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/13/aveo-pharmaceuticals-inc-aveo-short-interest-update-2.html.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.